-
Something wrong with this record ?
The Salutary Effects of Diminazene, Lisinopril or Valsartan on Cisplatin - Induced Acute Kidney Injury in Rats: A Comparative Study
Y. M. Al Suleimani, B. H. Ali, H. Ali, P. Manoj, K. S. Almashaiki, A. M. Abdelrahman
Status minimal Language English Country Czech Republic
Document type Journal Article, Comparative Study
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
PubMed Central
from 2020
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Acute Kidney Injury * chemically induced pathology metabolism prevention & control drug therapy MeSH
- Cisplatin * toxicity MeSH
- Diminazene * analogs & derivatives pharmacology therapeutic use MeSH
- Angiotensin-Converting Enzyme Inhibitors pharmacology MeSH
- Rats MeSH
- Kidney drug effects pathology metabolism MeSH
- Lisinopril * pharmacology MeSH
- Rats, Wistar * MeSH
- Antineoplastic Agents toxicity MeSH
- Valsartan * pharmacology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
Nephrotoxicity as a cause of acute kidney injury (AKI) induced by cisplatin (CP), limits its usefulness as an anticancer agent. Diminazene, an angiotensin converting enzyme 2 activator, exhibited renoprotective properties on rat models of kidney diseases. This research aims to investigate the salutary effect of diminazene in comparison with lisinopril or valsartan in CP-induced AKI. The first and second groups of rats received oral vehicle (distilled water) for 9 days, and saline injection or intraperitoneal CP (6 mg/kg) on day 6, respectively. Third, fourth, and fifth groups received intraperitoneal injections of CP on day 6 and diminazene (15 mg/kg/day, orally), lisinopril (10 mg/kg/day, orally), or valsartan (30 mg/kg/day, orally), for 9 days, respectively. 24h after the last day of treatment, blood and kidneys were removed under anesthesia for biochemical and histopathological examination. Urine during the last 24 h before sacrificing the rats was also collected. CP significantly increased plasma urea, creatinine, neutrophil gelatinase-associated lipocalin, calcium, phosphorus, and uric acid. It also increased urinary albumin/creatinine ratio, N-Acetyl-beta-D-Glucosaminidase/creatinine ratio, and reduced creatinine clearance, as well the plasma concentrations of inflammatory cytokines [plasma tumor necrosis factor-alpha, and interleukin-1beta], and significantly reduced antioxidant indices [catalase, glutathione reductase , and superoxide dismutase]. Histopathologically, CP treatment caused necrosis of renal tubules, tubular casts, shrunken glomeruli, and increased renal fibrosis. Diminazine, lisinopril, and valsartan ameliorated CP-induced biochemical and histopathological changes to a similar extent. The salutary effect of the three drugs used is, at least partially, due to their anti-inflammatory and antioxidant effects. Keywords: Cisplatin, Diminazene, ACE2 activator, Lisinopril, Valsartan, Acute kidney injury.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24009823
- 003
- CZ-PrNML
- 005
- 20250717122312.0
- 007
- ta
- 008
- 240606s2024 xr ad f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.935210 $2 doi
- 035 __
- $a (PubMed)38710058
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Al Suleimani, Y. M. $u Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Al Khod, Oman, yousufm@squ.edu.om
- 245 14
- $a The Salutary Effects of Diminazene, Lisinopril or Valsartan on Cisplatin - Induced Acute Kidney Injury in Rats: A Comparative Study / $c Y. M. Al Suleimani, B. H. Ali, H. Ali, P. Manoj, K. S. Almashaiki, A. M. Abdelrahman
- 520 9_
- $a Nephrotoxicity as a cause of acute kidney injury (AKI) induced by cisplatin (CP), limits its usefulness as an anticancer agent. Diminazene, an angiotensin converting enzyme 2 activator, exhibited renoprotective properties on rat models of kidney diseases. This research aims to investigate the salutary effect of diminazene in comparison with lisinopril or valsartan in CP-induced AKI. The first and second groups of rats received oral vehicle (distilled water) for 9 days, and saline injection or intraperitoneal CP (6 mg/kg) on day 6, respectively. Third, fourth, and fifth groups received intraperitoneal injections of CP on day 6 and diminazene (15 mg/kg/day, orally), lisinopril (10 mg/kg/day, orally), or valsartan (30 mg/kg/day, orally), for 9 days, respectively. 24h after the last day of treatment, blood and kidneys were removed under anesthesia for biochemical and histopathological examination. Urine during the last 24 h before sacrificing the rats was also collected. CP significantly increased plasma urea, creatinine, neutrophil gelatinase-associated lipocalin, calcium, phosphorus, and uric acid. It also increased urinary albumin/creatinine ratio, N-Acetyl-beta-D-Glucosaminidase/creatinine ratio, and reduced creatinine clearance, as well the plasma concentrations of inflammatory cytokines [plasma tumor necrosis factor-alpha, and interleukin-1beta], and significantly reduced antioxidant indices [catalase, glutathione reductase , and superoxide dismutase]. Histopathologically, CP treatment caused necrosis of renal tubules, tubular casts, shrunken glomeruli, and increased renal fibrosis. Diminazine, lisinopril, and valsartan ameliorated CP-induced biochemical and histopathological changes to a similar extent. The salutary effect of the three drugs used is, at least partially, due to their anti-inflammatory and antioxidant effects. Keywords: Cisplatin, Diminazene, ACE2 activator, Lisinopril, Valsartan, Acute kidney injury.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a akutní poškození ledvin $x chemicky indukované $x patologie $x metabolismus $x prevence a kontrola $x farmakoterapie $7 D058186
- 650 12
- $a lisinopril $x farmakologie $7 D017706
- 650 12
- $a cisplatina $x toxicita $7 D002945
- 650 12
- $a valsartan $x farmakologie $7 D000068756
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a diminazen $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D004133
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 12
- $a potkani Wistar $7 D017208
- 650 _2
- $a protinádorové látky $x toxicita $7 D000970
- 650 _2
- $a inhibitory ACE $x farmakologie $7 D000806
- 650 _2
- $a ledviny $x účinky léků $x patologie $x metabolismus $7 D007668
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Ali, B. H.
- 700 1_
- $a Ali, H.
- 700 1_
- $a Manoj, P.
- 700 1_
- $a Almashaiki, K. S.
- 700 1_
- $a Abdelrahman, A. M.
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 73, č. 2 (2024), s. 227-237
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38710058 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y - $z 0
- 990 __
- $a 20240606 $b ABA008
- 991 __
- $a 20250717122253 $b ABA008
- 999 __
- $a min $b bmc $g 2283486 $s 1219653
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 73 $c 2 $d 227-237 $e 20240430 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
- LZP __
- $b NLK116 $a Pubmed-20240606